How Many People Does the U.S. Imprison for Drug Use, and Who are They?

2005 ◽  
Vol 32 (3) ◽  
pp. 405-428 ◽  
Author(s):  
Jonathan P. Caulkins ◽  
Eric L. Sevigny

Data from the Survey of Inmates in Federal and State Correctional Facilities, 1997 are used to estimate the number of drug-law violators in U.S. prisons solely because of their drug use and not because of involvement in drug distribution or other offenses. The estimates (5,380 to 41,047) are much lower than would be implied by naively assuming that conviction for drug possession implies no involvement in drug distribution. Implied imprisonment risk per year of use is also low, perhaps an hour per year of use for marijuana, in part because expected time served is half that for those clearly involved in drug distribution.

1987 ◽  
Vol 44 (2) ◽  
pp. 349-353
Author(s):  
Thomas W. Woller ◽  
Michael J. Roberts ◽  
Pamela A. Ploetz

2004 ◽  
Vol 67 (5) ◽  
pp. 980-992 ◽  
Author(s):  
H. SCOTT HURD ◽  
STEPHANIE DOORES ◽  
DERMOT HAYES ◽  
ALAN MATHEW ◽  
JOHN MAURER ◽  
...  

The potential impact on human health from antibiotic-resistant bacteria selected by use of antibiotics in food animals has resulted in many reports and recommended actions. The U.S. Food and Drug Administration Center for Veterinary Medicine has issued Guidance Document 152, which advises veterinary drug sponsors of one potential process for conducting a qualitative risk assessment of drug use in food animals. Using this guideline, we developed a deterministic model to assess the risk from two macrolide antibiotics, tylosin and tilmicosin. The scope of modeling included all label claim uses of both macrolides in poultry, swine, and beef cattle. The Guidance Document was followed to define the hazard, which is illness (i) caused by foodborne bacteria with a resistance determinant, (ii) attributed to a specified animal-derived meat commodity, and (iii) treated with a human use drug of the same class. Risk was defined as the probability of this hazard combined with the consequence of treatment failure due to resistant Campylobacter spp. or Enterococcus faecium. A binomial event model was applied to estimate the annual risk for the U.S. general population. Parameters were derived from industry drug use surveys, scientific literature, medical guidelines, and government documents. This unique farm-to-patient risk assessment demonstrated that use of tylosin and tilmicosin in food animals presents a very low risk of human treatment failure, with an approximate annual probability of less than 1 in 10 million Campylobacter-derived and approximately 1 in 3 billion E. faecium–derived risk.


2003 ◽  
Vol 22 (3) ◽  
pp. 153-165
Author(s):  
Thomas W. Elwood

An analysis of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Its evolvement in the U.S. political context, particularly Congress, and its social ramifications are reviewed.


Author(s):  
Alfred W. McCoy

The current war on drugs being waged by the United States and United Nations rests upon a fundamental misunderstanding of the global nar­cotics traffic. In 1998, for example, the White House issued a National Drug Con­trol Strategy, proclaiming a 10-year program “to reduce illegal drug use and avail­ability 50 percent by the year 2007,” thereby achieving “the lowest recorded drug-use rate in American history.” To this end, the U.S. program plans to reduce foreign drug cultivation, shipments from source countries like Colombia, and smuggling in key transit zones. Although this strategy promises a balanced attack on both supply and demand, its ultimate success hinges upon the complete eradi­cation of the international supply of illicit drugs. “Eliminating the cultivation of il­licit coca and opium,” the document says in a revealing passage, “is the best ap­proach to combating cocaine and heroin availability in the U.S.” (U.S. Office of National Drug Control Policy 1998: 1, 23, 28). Similarly, in 1997 the new head of the United Nations Drug Control Program, Dr. Pino Arlacchi, announced a 10-year program to eradicate all illicit opium and coca cultivation, starting in Afghanistan. Three years later, in the United Nation’s World Drug Report 2000, he defended prohibition’s feasibility by citing China as a case where “comprehensive narcotics control strategies . . . succeeded in eradicat­ing opium between 1949 and 1954”— ignoring the communist coercion that al­lowed such success. Arlacchi also called for an “end to the psychology of despair” that questions drug prohibition, and insisted that this policy can indeed produce “the eradication of coca and opium poppy production.” Turning the page, however, the reader will find a chart showing a sharp rise in world opium production from 500 tons in 1981 to 6,000 tons in 2000— a juxtaposition that seems to challenge Ar-lacchi’s faith in prohibition (Bonner 1997; Wren 1998a, 1998b; United Nations 2000d, 1–2, 24). Examined closely, the United States and United Nations are pur­suing a drug control strategy whose success requires not just the reduction but also the total eradication of illicit narcotics cultivation from the face of the globe. Like the White House, the United Nations Drug Control Program (UNDCP) re­mains deeply, almost theologically committed to the untested proposition that the prohibition of cultivation is an effective response to the problem of illicit drugs.


2015 ◽  
Vol 39 (4) ◽  
pp. 679-687 ◽  
Author(s):  
Guilherme Borges ◽  
Sarah Zemore ◽  
Ricardo Orozco ◽  
Cheryl J. Cherpitel ◽  
Yu Ye ◽  
...  

1978 ◽  
Vol 20 (2) ◽  
pp. 107-131 ◽  
Author(s):  
Richard B. Craig

The problems associated with drug abuse in the United States have received considerable attention in recent years. By the mid-1970s, approximately 500,000 Americans were addicted to heroin, while at least 15 million were regular or casual users of marijuana. None of this heroin originates domestically, and only a small percentage of the marijuana, and this of low potency, is home-grown. Consequently, the question of source has become cardinal to most analyses of drug use and abuse in the United States.Mexico has long been the primary source of high potency marijuana for the American market. Despite the recent influx from Jamaica and Colombia, Mexico still supplies an estimated 70% of the annual American consumption, or some 10 million pounds. More importantly, Mexico is currently the source of 70% to 80% of the heroin on the U.S. market, an alarming 6-8 ton annual figure. Furthermore, Mexico is both a primary transshipment route for cocaine, an increasingly popular drug originating in South America, and the source of vast quantities of psychotropic substances.


2021 ◽  
pp. 1-13
Author(s):  
Maria Pisu ◽  
Roy C. Martin ◽  
Liang Shan ◽  
Giovanna Pilonieta ◽  
Richard E. Kennedy ◽  
...  

Background: Use of specialists and recommended drugs has beneficial effects for older adults living with Alzheimer’s disease and related dementia (ADRD). Gaps in care may exist for minorities, e.g., Blacks, and especially in the United States (U.S.) Deep South (DS), a poor U.S. region with rising ADRD cases and minority overrepresentation. Currently, we have little understanding of ADRD care utilization in diverse populations in this region and elsewhere in the U.S. (non-DS), and the factors that adversely impact it. Objective: To examine utilization of specialists and ADRD drugs (outcomes) in racial/ethnic groups of older adults with ADRD and the personal or context-level factors affecting these outcomes in DS and non-DS. Methods: We obtained outcomes and personal-level covariates from claims for 127,512 Medicare beneficiaries with ADRD in 2013–2015, and combined county-level data in exploratory factor analysis to define context-level covariates. Adjusted analyses tested significant association of outcomes with Black/White race and other factors in DS and non-DS. Results: Across racial/ethnic groups, 33%–43% in DS and 43%–50% in non-DS used specialists; 47%–55% in DS and 41%–48% in non-DS used ADRD drugs. In adjusted analyses, differences between Blacks and Whites were not significant. Vascular dementia, comorbidities, poverty, and context-level factor “Availability of Medical Resources” were associated with specialist use; Alzheimer’s disease and senile dementia, comorbidities, and specialist use were associated with drug use. In non-DS only, other individual, context-level covariates were associated with the outcomes. Conclusion: We did not observe significant gaps in ADRD care in DS and non-DS; however, research should further examine determinants of low specialist and drug use in these regions.


PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0258183
Author(s):  
Khin Zar Khaing Thein ◽  
Chantal Herberholz ◽  
Win Pa Sandar ◽  
Yadanar

Drug use disorder (DUD) is a serious health condition that imposes a heavy burden on the persons who have a drug addiction experience and their families, especially in countries, such as Myanmar, where few formal support mechanisms are in place and repressive drug laws exacerbate the situation. Yet, in Myanmar, little is known about how informal caregivers are affected. This qualitative study aims at exploring the socioeconomic and psychological burden that informal caregivers in Myanmar encounter, coping strategies they employ, as well as barriers to coping they face. Thirty primary informal caregivers were chosen purposively from a mental health hospital in Yangon for in-depth interviews. The recorded interviews were transcribed and the data were analysed using framework analysis. The results revealed that financial constraint, income loss, social limitation and negative impact on family cohesion are important dimensions of socioeconomic burden, whereas sadness, anger, helplessness, worry, fear and guilt are the main psychological distress factors encountered by caregivers of persons with DUD. Key coping strategies employed by caregivers include religious coping, financial coping, acceptance and planning. Moreover, perceived stigma towards persons with DUD and their caregivers was very high and caregivers received hardly any social support, inter alia because of the country’s drug law which reinforces stigma and discrimination. Neither the government nor any other organization in Myanmar provided financial support to the caregivers. The results of this study showed that caring for persons with DUD has devastating effects on caregivers and their families. While the 2018 National Drug Control Policy can potentially help alleviate the burden on substance users and their families, further amendments of the existing drug law are urgently needed. Moreover, strengthening prevention and harm reduction approaches, improving treatment and rehabilitation services, as well as stigma-reducing educational campaigns should be considered a priority.


Sign in / Sign up

Export Citation Format

Share Document